Bloomberg BNA’s Corporate Law & Accountability Report is available on the Corporate Law Resource Center. This news service keeps corporate practitioners informed of legal developments of...
By Anjali Cordeiro and Sophia Pearson
Sept. 16 — Allergan Inc. and its two hostile bidders, Pershing Square Capital Management LP and Valeant Pharmaceuticals International Inc., agreed the maker of Botox would hold a shareholder meeting Dec. 18 that could shape the outcome of their $54 billion takeover proposal.
Shareholders will be able to “express their opinion on the value proposition offered by Valeant,” Allergan said in a statement Sept. 16. Pershing Square and Valeant, which had objected to the date set by Allergan, agreed to dismiss a pending lawsuit in the Delaware Chancery Court ahead of a scheduled Oct. 6 trial. The agreement couldn't immediately be verified in court records (PS Fund 1 LLC v. Allergan Inc.,Del. Ch., C.A. No. 10057-CB, 9/2/14).
Valeant teamed up with investor Bill Ackman's Pershing Square to help drive the hostile takeover. The December meeting will allow Allergan shareholders to vote on whether to replace members of the drugmaker's board as part of the contentious takeover fight.
“Today's announcement eliminates the distraction and cost of unnecessary litigation,” Allergan said in the statement. The Irvine, California-based drugmaker also repeated its recommendation that holders “prevent Valeant from taking control of Allergan at a price that does not appropriately reflect the underlying value of Allergan's assets, operations and prospects.”
The two sides have fought for months as Allergan repeatedly rejected Valeant's unsolicited offer. Ackman has sought the special meeting to remove most of the company's board and add six new directors.
Last month, the Delaware Chancery Court's Andre Bouchard set the Oct. 6 trial date to decide whether Ackman and Valeant had enough support from Allergan shareholders to force a special meeting before December.
Valeant, based in Laval, Quebec, wants to buy Allergan to expand its portfolio and become one of the world's largest drugmakers. David Pyott, Allergan's chief executive officer, has fought to keep the company independent, announcing a restructuring including cutting 1,500 jobs.
In a letter to Chancellor Bouchard on Sept. 14, Allergan said questions about Valeant's business model and practices were necessary at trial. The company said it had “substantial concerns” about Valeant's business model, its lack of commitment to research and development, its opaque accounting and the company's reliance on serial acquisitions.
Allergan directors were prepared to testify about the importance for shareholders to consider these issues in advance of a special meeting “as roughly 60 percent of the proposed merger” is in the form of Valeant stock, according to the letter.
Pershing Square has delivered requests calling for a special meeting from 51 institutions representing 35.68 percent of Allergan's common stock, it said in a joint statement with Valeant. Moreover, two shareholder advisory groups have recommended that Allergan investors back the special meeting pushed by Ackman.
At the December meeting, Allergan shareholders will have the opportunity to weigh in on issues such as a request that Allergan engage in negotiations with Valeant and Pershing Square, and the appointment of an independent slate of directors, Valeant and Pershing said in their statement.
Calls to Valeant, Pershing Square and Allergan went unanswered outside of regular business hours.
With assistance from Natasha Khan in Hong Kong and Jef Feeley in Wilmington, Delaware
©2014 Bloomberg L.P. All rights reserved. Used with permission.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)